Gene Therapy Pioneer Bluebird Bio Plots Bold New Future Under Fresh Ownership
Bluebird Bio, a leader in gene therapy, has been acquired by Carlyle Group and SK Capital Partners. The acquisition offers stockholders a $3.00 per share cash payout, potentially reaching $9.84 based on performance. Facing financial challenges, this deal provides Bluebird with the
